BioCryst Pharmaceuticals, Inc. (BCRX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -62.14M | 276.04M | 41.11M | 41.3M | -27.52M | -5.21M | 8.24M | -1.37M | -53.68M | -8.92M | -19.9M | -18.81M |
| Operating CF Margin % | -39.73% | 67.9% | 25.79% | 25.28% | -18.91% | -3.96% | 7.04% | -1.25% | -57.87% | -9.55% | -22.94% | -22.81% |
| Operating CF Growth % | -125.81% | 5395.15% | 398.62% | 3119.15% | 48.74% | 41.55% | 141.44% | 92.73% | -12.99% | 62.61% | 38.67% | 32.22% |
| Net Income | -721.81M | 362.26M | 12.9M | 5.08M | 32K | -26.8M | -14.03M | -12.67M | -35.38M | -61.73M | -36.15M | -75.33M |
| Depreciation & Amortization | 1.06M | 4.04M | 335K | 329K | 331K | 309K | 311K | 320K | 306K | 423K | 420K | 407K |
| Stock-Based Compensation | 0 | 72.57M | 0 | 21.3M | 21.37M | 21.34M | 17.25M | 13.17M | 13.65M | 16.49M | 12.28M | 12.84M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 730.02M | -167.07M | 29.25M | 12.21M | 12.88M | 11.27M | 13.85M | 16.11M | 16.26M | 17.8M | 19.75M | 49.91M |
| Working Capital Changes | -71.4M | 4.23M | -1.37M | 2.38M | -62.13M | -11.33M | -9.13M | -18.3M | -48.52M | 18.1M | -16.2M | -6.64M |
| Change in Receivables | -474K | -15.49M | -17K | -7.31M | -13.99M | -7.3M | -3.32M | -8.25M | -3.84M | -2.97M | 3.84M | -8.99M |
| Change in Inventory | -4.85M | -515K | -1.69M | 1.44M | -870K | -2.16M | -1.52M | 739K | -1.22M | 907K | -3.39M | 898K |
| Change in Payables | -60.4M | 35.36M | 24.58M | 45.01M | -47.14M | -2.45M | 0 | 0 | 0 | 19.87M | 0 | -188K |
| Cash from Investing | -268.65M | -83.49M | 13.57M | 29.13M | 27.09M | 17.8M | 8.49M | -2.45M | 28.76M | -28.47M | 23.12M | -19.04M |
| Capital Expenditures | -403K | -802K | -1.34M | -179K | -143K | -675K | -59K | -155K | -235K | -554K | -987K | -467K |
| CapEx % of Revenue | 0.26% | 0.2% | 0.84% | 0.11% | 0.1% | 0.51% | 0.05% | 0.14% | 0.25% | 0.59% | 1.14% | 0.57% |
| Acquisitions | -489.48M | -6.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 550K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 412.9M | -202.04M | -58.3M | -73.69M | 529K | -4.02M | 1.27M | -1.97M | -1.05M | -3.17M | 1.23M | 29.36M |
| Debt Issued (Net) | 394.57M | -196.71M | -60.34M | -70.04M | -516K | -356K | -556K | -402K | -390K | -1.17M | 0 | 27.4M |
| Equity Issued (Net) | 19.51M | 680K | 2.67M | 9K | 6K | 5K | 6K | 12K | 11K | 0 | 11K | 1.95M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.19M | -6M | -628K | -3.65M | 1.04M | -3.67M | 1.82M | -1.58M | -669K | -2.01M | 1.21M | 0 |
| Net Change in Cash | 82.51M | -83.06M | -3.87M | -16.96M | 558K | 7.26M | 18.86M | -5.93M | -26.32M | -40.04M | 4.7M | -8.81M |
| Free Cash Flow | -62.54M | 275.23M | 39.77M | 41.12M | -27.66M | -5.89M | 8.19M | -1.52M | -53.92M | -9.47M | -20.88M | -19.28M |
| FCF Margin % | -39.98% | 67.7% | 24.95% | 25.17% | -19.01% | -4.48% | 6.99% | -1.39% | -58.13% | -10.14% | -24.08% | -23.37% |
| FCF Growth % | -126.1% | 4774.49% | 385.79% | 2800.13% | 48.7% | 37.84% | 139.2% | 92.1% | -13.1% | 61.14% | 35.98% | 31.14% |
| FCF per Share | -0.26 | 1.26 | 0.18 | 0.19 | -0.13 | -0.03 | 0.04 | -0.01 | -0.26 | -0.05 | -0.11 | -0.10 |
| FCF Conversion (FCF/Net Income) | 0.09x | 1.12x | 3.19x | 8.12x | -859.91x | 0.19x | -0.59x | 0.11x | 1.52x | 0.14x | 0.55x | 0.25x |
| Interest Paid | 0 | 0 | 0 | 7.53M | 9.15M | 10.14M | 10.2M | 5.05M | 4.99M | 0 | 4.85M | 0 |
| Taxes Paid | 0 | 0 | 0 | 1.23M | 1K | 378K | 360K | 679K | 186K | 0 | 318K | 0 |